# AULBIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aulbio

- Industry: Biotechnology
- Headquarters: Seongnam-si, South Korea
- Website: www.aulbio.com/
- Total disclosed funding: $14M
- Latest round: Series C (Dec 29, 2025)
- Investors on record: 7

## About

Founded in 2018 and based in Seongnam, South Korea, AULBIO is a biotechnology research company specializing in research, development, and commercialization of formulated brand products based on drug delivery technology. In December 2025, AULBIO raised KRW 11.2 billion in series C funding from new investors Partners Investment and IBK Capital, with participation from returning investor Medici Investment. Other unspecified investors also participated in the round.

The firm develops and commercializes long-acting biopharmaceuticals using its proprietary microsphere platform technology based on its drug delivery technology (DDS). The firm offers long-acting injectable microspheres based on biodegradable microspheres containing peptide drugs that reduce the number of daily injections to monthly injections for conditions like diabetes, obesity, and prostate cancer.

## Funding rounds

- Series C, Dec 29, 2025, $7.7M — Partners Investment, IBK Capital, Medici Investment
- Series A, Jan 28, 2022, $6M — Industrial Bank of Korea, ES Investor, Enlight Ventures, Kyung Dong Pharmaceutical

## Investors

- Industrial Bank of Korea — Series A
- ES Investor (https://capitalatlas.ai/funds/es-investor) — Series A
- Enlight Ventures (https://capitalatlas.ai/funds/enlight-ventures) — Series A
- Kyung Dong Pharmaceutical — Series A
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series C
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series C
- Medici Investment (https://capitalatlas.ai/funds/medici-investment) — Series C